Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Final programming Document

https://www.ema.europa.eu/en/documents/report/final-programming-document-2022-2024_en.pdf

Marie Berger 13 September 2022 All news
  • ← Guidance on releasing information from adverse reaction and medical device incident reports to the public
  • Meeting highlights from the CHMP – 12-15 September 2022 →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 – CTIS Training Programme – Module 01
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 February 2025
  • CHARGE(E) DE PHARMACOVIGILANCE HYBRIDE
Copyright © 2018 - Pharmya - Legal terms - Quality Policy